3 results match your criteria: "Centre Hospitalo-Universitaire Le Bocage[Affiliation]"
Role of positron emission tomography for the monitoring of response to therapy in breast cancer.
Oncologist
February 2015
Departments of Nuclear Medicine and Medical Oncology, Centre G.F. Leclerc, Dijon, France; Imaging Department, Centre Hospitalo-Universitaire Le Bocage, Dijon, France; Université de Bourgogne, UMR CNRS 6306, Dijon, France.
This review considers the potential utility of positron emission tomography (PET) tracers in the setting of response monitoring in breast cancer, with a special emphasis on glucose metabolic changes assessed with (18)F-fluorodeoxyglucose (FDG). In the neoadjuvant setting of breast cancer, the metabolic response can predict the final complete pathologic response after the first cycles of chemotherapy. Because tumor metabolic behavior highly depends on cancer subtype, studies are ongoing to define the optimal metabolic criteria of tumor response in each subtype.
View Article and Find Full Text PDFEfficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients.
J Antimicrob Chemother
January 1993
Department of Hematology, Centre Hospitalo-Universitaire Le Bocage, Dijon, France.
The efficacy and tolerance of a new amphotericin B lipid emulsion (AmB-IL) in which amphotericin B was diluted in a lipid solution for parenteral nutrition (Intralipid) was assessed in fourteen episodes of candidaemia occurring in neutropenic patients. The strains isolated were Candida krusei (nine cases), Candida albicans (three cases), Candida parapsilosis (one case) and Candida lusitaniae (one case). An AmB-IL was administered at a mean dosage of 1.
View Article and Find Full Text PDFSufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM.
Cancer
October 1991
Unité d'Hématologie Clinique, Centre Hospitalo-Universitaire Le Bocage, Dijon, France.
Article Synopsis
- Several agents have been explored for reversing multidrug resistance (MDR) in cancer treatments, but their toxicity limits their effectiveness in patients.
- Quinine, an antimalarial drug, has been shown to reverse resistance to doxorubicin in a specific human leukemic cell line (K562/ADM) and requires a nontoxic dose of 5 micrograms/ml for effectiveness.
- Clinical trials suggest that administering quinine 24 to 36 hours before chemotherapy could improve the uptake of cancer drugs and enhance treatment outcomes for patients with hematologic cancers.